Just like Hurricane Harvey, COVID-19 is causing Houstonians to rethink how they operate — and that tech and innovation inversion is opening the door to new opportunities. Photo via Getty Images

For has long as I can remember, I had to live near water. That's why I moved to Houston. Recently, new neighbors moved next door from the downtown Galleria area. They loved it there until coronavirus turned shopping habits into stay-at-home habits. The experience led them to recognize they could do just fine without the Galleria-area routine, pivoting instead to a maritime lifestyle.

Could COVID-19 be triggering an inversion paradigm? An inversion paradigm puts needs first rather than product first. We have experienced many historic technology inversions. Remember when our televisions were air-wave dependent and telephones were tethered to the wall? Because the need evolved for a phone that was mobile, today our TV's are wired, and our telephones are untethered.

This technology inversion fundamentally found its way to the individual consumer and transformed entire industries. Houston businesses are responding to a rare COVID-19-induced disruption. Inversions are rare, but when they occur, opportunity follows.

Large infrastructure challenges are normally led by bureaucratic funding processes that result in productized solutions. Hurricane Harvey was a wake-up call to take decisive action to protect decades of private and public investment against future flood events. It was an analogue to removing the board with the nail in it from the driveway to avoid endless tire repairs.

Now, Houston's resilience infrastructure is going through a Hurricane Harvey-induced inversion. The fundamental approach to water management is experiencing a historic reversal which focuses on need rather than a response cycle. Largely dependent on surface run-off systems, Houston experienced a river running through it during Hurricane Harvey. In response, studies and projects are underway to consider a major underground storm drainage system. Water management is fundamentally changing to move stormwater from above ground to below grade, while domestic water is moving away from underground sources to surface supplies, such as lakes. These programs reduce threats to downtown, allowing urbanism and businesses to flourish, simply by addressing a human need in lieu of building another drainage product.

Fortunately for the Houston economy, pre-COVID, quasi-inversion programs already in place to address mobility needs, such as the $7.5 billion METRONext program and $4.8 billion for flood control essentials, are injecting billions of dollars into the local economy. At the federal level, future stimulus funding designed to address infrastructure needs and the economic impact of Coronavirus are likely to follow next year. Consequently, the current Hurricane Harvey, COVID-19 inversion could position Houston to rebound from a time of trial reimagining what a next generation city in the modern age should look like.

Graphic courtesy of AECOM

In fact, infrastructure programs have a long history of creating sustainable jobs and transforming cities. Did you know the River Walk in San Antonio, a downtown centerpiece that thrives today and contributes to thousands of job opportunities, was a construction project born during the Great Depression to address a disastrous flood occurring in the early 1920s? San Antonio architect Robert H. H. Hugman was elected to address a need to save lives and reimagine San Antonio's downtown. The city was altered forever by creating a flood resilience infrastructure that also transformed its city center into a civic gathering place that made San Antonio one of the largest destination cities in Texas.

While technology inversions are occurring more often than before, they are still rare, and each one is very important. Infrastructure inversions that transform cites are even more exceptional. In a COVID-19-induced inversion period, the possibilities are limitless, and the time is now. With programs underway and potential stimulus funding to support additional investment to address city needs, Houston is positioned for something amazing.

------

Tony Loyd is based in Houston and vice president at AECOM.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.